# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2091-2100 of 2224 results.
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Status: Active, not recruiting
Last Changed: May 15, 2019
First Received: Nov 28, 2013
Disease(s): Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Intervention(s): Romidepsin, Oral 5-Azacitidine
Locations: Columbia University Medical Center, New York, New York, United States
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
Status: Active, not recruiting
Last Changed: Jul 24, 2019
First Received: Dec 22, 2011
Disease(s): Leukemia, Lymphoma
Intervention(s): HSCT, DLI
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
Status: Completed
Last Changed: Jan 29, 2010
First Received: Nov 10, 2005
Disease(s): Non-Hodgkin's Lymphoma
Intervention(s): Rituxan, 1018 ISS
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pesticide Associated Lymphomas: Expression of Treatment Resistance Genes
Status: Completed
Last Changed: Apr 18, 2019
First Received: Jul 24, 2018
Disease(s): Lymphoma Diffuse Large B-cell
Locations: Uhmontpellier, Montpellier, France
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
Status: Not yet recruiting
Last Changed: Apr 02, 2019
First Received: Apr 02, 2019
Disease(s): Richter Syndrome
Intervention(s): Acalabrutinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Rituximab
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
Status: Recruiting
Last Changed: Sep 07, 2020
First Received: Sep 11, 2018
Disease(s): Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Intervention(s): PBCAR0191, Fludarabine, Cyclophosphamide
Locations: City of Hope, Duarte, California, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Northside Hospital Cancer Institute, Atlanta, Georgia, United States
Indiana Blood and Marrow, Indianapolis, Indiana, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
... and 4 other locations.
PET Study in Patients With Non-Hodgkin Lymphoma
Status: Completed
Last Changed: Feb 26, 2013
First Received: Jul 10, 2008
Disease(s): Lymphoma
Intervention(s): fluorine 18-fludeoxyglucose positron emission tomography
Locations: Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Status: Completed
Last Changed: Dec 30, 2019
First Received: Sep 21, 2009
Disease(s): Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
Intervention(s): rituximab, bortezomib, cladribine
Locations: The University of Arizona Cancer Center, Tucson, Arizona, United States
Study of IV CBL0137 in Previously Treated Hematological Subjects
Status: Suspended
Last Changed: May 21, 2020
First Received: Oct 12, 2016
Disease(s): Hematological Malignancies
Intervention(s): CBL0137
Locations: The Oncology Institute of Hope & Innovation, Whittier, California, United States
Claude Sportes, Augusta, Georgia, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
University Hospitals Case Medical, Cleveland, Ohio, United States
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.
Status: Terminated
Last Changed: Oct 24, 2012
First Received: Aug 27, 2008
Disease(s): Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, B-cell Precursor Acute Lymphoblastic Leukaemia, T-cell Non-Hodgkin's Lymphoma
Intervention(s): Forodesine
Locations: Vienna, Austria
Prague, Czech Republic
Prof Gerard Michel, Marseilles, France
Charite Universitymedicine, Berlin, Germany
Dr Giovanna Gioriani, Pavia, Italy
... and 2 other locations.